



PIPER RUDNICK^{LLP}
1200 NINETEENTH STREET, NW
WASHINGTON, DC 20036-2412
TELEPHONE: 202-861-3900
FACSIMILE: 202-223-2085

DOCKET NO.: K&S-0100-US

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

RECEIVED

APR 15 2002

TECH CENTER 1600/2900

Re: Serial No.: 09/742,424
Applicant(s): Ram PRATAP, et al.
Filing Date: December 22, 2000
For: NOVEL USES OF GUGULIPID: AS COGNITION ENHANCER,
ANTI-HYPERGLYCEMIC AND FOR DERMAL CONDITIONS
Group Art Unit: 1615
Examiner: Todd Ware

SIR:

Attached hereto for filing are the following papers:

RESPONSE TO RESTRICTION REQUIREMENT

Our check in the amount of \$ -0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 50-1442. Further, if these papers are not considered timely filed, then a request is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

PIPER RUDNICK LLP

Wilburn L. Chesser
Attorney of Record
Registration No.: 41,668

Paul C. Kimball
Registration No.: 34,641



DOCKET NO. R&S-0100-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Ram PRATAP, et al.

ART UNIT: 1615

SERIAL NO.: 09/742,424

EXAMINER: Todd Ware

FILING DATE: December 22, 2000

FOR: NOVEL USES OF GUGULIPID: AS COGNITION ENHANCER, ANTI-HYPERGLYCEMIC AND FOR DERMAL CONDITIONS

#5
SUG
4-18-02

RESPONSE TO RESTRICTION REQUIREMENT

RECEIVED

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

APR 15 2002

TECH CENTER 1600/2900

SIR:

Responsive to the Restriction Requirement dated March 12, 2002, Applicants elect, albeit with traverse, Group I, Claims 1-12, for further prosecution at this time. This Response is timely filed on or before April 12, 2002.

REMARKS

The Examiner has required restriction in the above-identified application as follows:

- Group I: Claims 1-12, drawn to a method of controlling cognitive dysfunction, hyperglycemia, and some infective conditions of the skin in mammals;
- Group II: ¹³⁻²¹ drawn to a method of reducing hyperglycemic conditions;
- Group III: Claims 22-23, drawn to a method of reducing fungal infections;
- and
- Group IV: Claims 24-28, drawn to a method of obtaining gugulipid and ethyl acetate extract of resin.